Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA7 | P43166 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.56 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 2/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1261188 | 0.87 | LMNA (0.59) | LMNACYP1A2CYP3A4MAOACA12 | |
| SCHEMBL28417178 | 0.84 | CA12 (0.61) | LMNACYP1A2CYP3A4MAOACA12 | |
| SCHEMBL30582428 | 0.84 | LMNA (0.65) | LMNACYP1A2CYP3A4MAOACA12 | |
| SCHEMBL940578 | 0.84 | LMNA (0.65) | LMNACYP1A2CYP3A4MAOACA12 | |
| SCHEMBL8284386 | 0.83 | CA12 (0.59) | LMNACYP1A2CYP3A4MAOACA12 | |
| SCHEMBL1927097 | 0.83 | LMNA (0.62) | LMNACYP1A2CYP3A4MAOACA12 | |
| SCHEMBL14841131 | 0.81 | CA12 (0.57) | LMNACYP1A2CYP3A4MAOACA12 | |
| SCHEMBL1313506 | 0.81 | CA12 (0.72) | LMNACYP1A2CYP3A4MAOACA12 | |
| SCHEMBL31890210 | 0.81 | CA1 (0.72) | LMNACYP1A2CYP3A4MAOACA12 | |
| SCHEMBL2708353 | 0.81 | CA1 (0.72) | LMNACYP1A2CYP3A4MAOACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2238109-B1 | 6-SUBSTITUTED INDOLE-3-CARBOXYLIC ACID AMIDE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN INC (US) | 2014-12-31 | — | — | EP | disclosed |
| US-20130338158-A1 | 6-SUBSTITUTED INDOLE-3-CARBOXYLIC ACID AMIDE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8524917-B2 | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | ALLERGAN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524917-B2 | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | ALLERGAN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524917-B2 | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | ALLERGAN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| CN-102099333-A | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity | ALLERGAN INC | 2011-06-15 | — | — | CN | disclosed |
| EP-2238109-A1 | 6-SUBSTITUTED INDOLE-3-CARBOXYLIC ACID AMIDE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2010-10-13 | — | — | EP | disclosed |
| CN-101668741-A | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity | ALLERGAN INC | 2010-03-10 | — | — | CN | disclosed |
| EP-2125723-A1 | 6-SUBSTITUTED INDOLE-3-CARBOXYLIC ACID AMIDE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | Allergan, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009088531-A1 | 6-SUBSTITUTED INDOLE-3-CARBOXYLIC ACID AMIDE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| CN-101460458-A | Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | ALLERGAN INC (US) | 2009-06-17 | — | — | CN | disclosed |
| EP-1984334-A2 | INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | Allergan, Inc. (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2008089015-A1 | 6-SUBSTITUTED INDOLE-3-CARBOXYLIC ACID AMIDE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171772-A1 | e.g. Methyl 1-Benzyl-6-methoxy-1H-indole-2-carboxylate; glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, wound healing, platelet aggregation and thrombosis | ALLERGAN, INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080171772-A1 | e.g. Methyl 1-Benzyl-6-methoxy-1H-indole-2-carboxylate; glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, wound healing, platelet aggregation and thrombosis | ALLERGAN, INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080171772-A1 | e.g. Methyl 1-Benzyl-6-methoxy-1H-indole-2-carboxylate; glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, wound healing, platelet aggregation and thrombosis | ALLERGAN, INC. | 2008-07-17 | — | — | US | disclosed |
| WO-2007095561-A2 | INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171772-A1 | e.g. Methyl 1-Benzyl-6-methoxy-1H-indole-2-carboxylate; glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, wound healing, platelet aggregation and thrombosis | PTGIR, S1PR1, TBXA2R | LMNA 3042/4885CYP1A2 712/4885CYP3A4 1490/4885 |
| US-20130338158-A1 | 6-SUBSTITUTED INDOLE-3-CARBOXYLIC ACID AMIDE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | S1PR1, S1PR3, S1PR2 | LMNA 2882/4885CYP1A2 1905/4885CYP3A4 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.